[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637618":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":29,"locations":37,"responsibleParty":89,"collaborators":11,"id":91,"slug":11,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":11,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Eyconis INC.","OTHER",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"EYC-0305 Dose Level 1","EXPERIMENTAL",null,[13],"Biological: EYC-0305",{"label":15,"type":10,"description":11,"interventionNames":16},"EYC-0305 Dose Level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"EYC-0305 Dose Level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"EYC-0305 Dose Level 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","EYC-0305","Extended-delivery anti-VEGF",[9,15,18,21],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Kim Reed, OD, FAAO","CONTACT","1-866-392-6647","info@eyconis.com",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":34},"Karen Chu, MS",[38,51,61,71,80],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":11},"Beverly Hills, CA","RECRUITING","Beverly Hills","California","90211","United States",{"type":46,"coordinates":47},"Point",[48,49],-118.40036,34.07362,{"lat":49,"lon":48},{"facility":52,"status":40,"city":53,"state":54,"zip":55,"country":44,"cosmosGeoPoint":56,"geoPoint":60,"contacts":11},"Erie, PA","Erie","Pennsylvania","16505",{"type":46,"coordinates":57},[58,59],-80.08506,42.12922,{"lat":59,"lon":58},{"facility":62,"status":40,"city":63,"state":64,"zip":65,"country":44,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Bellaire, TX","Bellaire","Texas","77401",{"type":46,"coordinates":67},[68,69],-95.45883,29.70579,{"lat":69,"lon":68},{"facility":72,"status":40,"city":73,"state":64,"zip":74,"country":44,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"McAllen, TX","McAllen","78503",{"type":46,"coordinates":76},[77,78],-98.23001,26.20341,{"lat":78,"lon":77},{"facility":81,"status":40,"city":82,"state":64,"zip":83,"country":44,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"The Woodlands, TX","The Woodlands","77384",{"type":46,"coordinates":85},[86,87],-95.48938,30.15799,{"lat":87,"lon":86},{"type":90,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100637618",false,"NCT07587515","Phase 1b\u002F2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration","Open-Label, Multiple Ascending Dose Phase 1b\u002F2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration","OVERTURE","Inclusion Criteria:\n\n* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria\n* Willing and able to comply with clinic visits and study-related procedures\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity or known allergy that would preclude study drug administration\n* Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access\n* Uncontrolled diabetes mellitus\n* History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit\n* Renal failure, dialysis, or history of renal transplant\n* Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion\n* Pregnant or breastfeeding women","ALL","50 Years",{"count":101,"type":102},30,"ESTIMATED","INTERVENTIONAL",[105,106],"PHASE1","PHASE2","This Phase 1b\u002F2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.",[109],"Neovascular (Wet) Age-Related Macular Degeneration",[26,111,112,113,114,115,116],"TransCon aVEGF","wet AMD","neovascular AMD","treatment naive","Eyconis","anti-VEGF","2026-06-25",{"date":119,"type":120},"2026-06-29","ACTUAL",{"date":122,"type":120},"2026-05-19",{"date":124,"type":102},"2028-05",{"name":5,"class":6},5]